Comparison of the Effects of Standardized Chokeberry Extracts With Various Formulations on the Levels of Selected Markers Associated With Cardiovascular Disease
NCT ID: NCT05988099
Last Updated: 2023-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2023-02-20
2023-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Extracts of Amla, Walnut Leaf, Red Yeast Rice and Olive in Cardiovascular Prevention
NCT06333158
Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia
NCT02989753
The Effect of Olive Leaf Extract Administration on Cardiovascular Health
NCT02990637
Effect of Olivomed (Olive Extract) on Endothelial, Cardiac and Vascular Function
NCT04520126
Evaluation of the Functionality of an Extract Rich in Phytosterols and Phytostanols on Parameters Related to the Lipid Profile of Individuals With Hypercholesterolemia, Mainly in the Levels of Total Cholesterol, LDL Cholesterol and Oxidized LDL
NCT06954649
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Complex product (chokeberry extract, L-arginine, vitamin E, vitamin A, folic acid, chromium)
Single oral dose - 2 capsules
Complex product
400 mg of chokeberry extract in liposomal formulation and L-arginine, vitamin E, vitamin A, folic acid, chromium
Chokeberry extract in liposomal formulation
Single oral dose - 2 capsules
Chokeberry extract in liposomal formulation
400 mg of chokeberry extract in liposomal formulation
Chokeberry extract in traditional formulation
Single oral dose - 2 capsules
Chokeberry extract in traditional formulation
400 mg of chokeberry extract in traditional formulation
Placebo
Single oral dose - 2 capsules
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Complex product
400 mg of chokeberry extract in liposomal formulation and L-arginine, vitamin E, vitamin A, folic acid, chromium
Chokeberry extract in liposomal formulation
400 mg of chokeberry extract in liposomal formulation
Chokeberry extract in traditional formulation
400 mg of chokeberry extract in traditional formulation
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with known: hypertension or hypercholesterolemia,
* Patients on hypotensive or hypolipemic therapy for at least 6 months prior to study enrollment
* Signed informed consent
Exclusion Criteria
* Intake of supplements with antioxidant properties,
* Participation in another clinical trial,
* Women who are pregnant, planning to become pregnant during the study, or breastfeeding,
* Oncological disease, autoimmune disease, severe liver dysfunction, tuberculosis, leukemia, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplant,
* Patients receiving glucocorticosteroids, anti-allergic drugs, non-steroidal anti-inflammatory drugs in exacerbations of chronic disease.
* Patients with signs of inflammation such as increased body temperature, redness, swelling, pain.
* Patients who have not given written consent to participate in the study.
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AronPharma Sp. z o. o.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centum Zdrowia Eter-Med sp. z o.o.
Gdansk, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04-AP-MEL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.